A bankruptcy judge approved the sale of 23andMe's assets and business operations to a nonprofit led by 23andMe's co-founder ...

Former 23andMe CEO Anne Wojcicki now runs TTAM Research Institute, which outbid Regeneron in an auction for the bankrupt ...

23andMe co-founder and former CEO Anne Wojcicki is set to buy back the company after it filed for Chapter 11 bankruptcy protection earlier this year. On Friday, 23andMe and TTAM Research Institute ...

Anne Wojcicki regains control of 23andMe, the company she co-founded and led as CEO, through her nonprofit TTAM with a $305 million bid at a bankruptcy auction.

Maintaining control of the company's assets has been Wojcicki's plan since 23andMe declared bankruptcy in March 2025. She originally resigned as the company's CEO to make a bid on the company.

Former 23andMe CEO Anne Wojcicki 's attempt to keep control of the company — including the personal genetic data of millions of 23andMe customers — was approved by a U.S. Bankruptcy Court ...

Anne Wojcicki's winning bid to reclaim control of 23andMe doesn't necessarily end the fight over what happens to the DNA of 15 million people collected by the bankrupt consumer genomics company.

Anne Wojcicki, the co-founder and former CEO of 23andMe MEHCQ -0.51%, is poised to regain control of the DNA-testing company after a nonprofit she controls topped a prior bid.

From the San Francisco Business Times. 23andMe co-founder Anne Wojcicki is back in control of the genetic-testing company. A nonprofit led by Wojcicki — who launched the consumer DNA-test ...

The transaction — which arrives more than three months after 23andMe filed for Chapter 11 bankruptcy — is set to officially ...

Anne Wojcicki is set to regain control of 23andMe after a $305 million bid from a nonprofit she controls topped Regeneron Pharmaceuticals' offer for the DNA-testing company in a bankruptcy auction.

Anne Wojcicki, the co-founder and former CEO of 23andMe, has regained control over the embattled genetic testing company after her new nonprofit, TTAM Research Institute, outbid Regeneron ...